
NanoViricides President Discusses Broad-Spectrum Antiviral Platform and Upcoming Clinical Trials
NanoViricides President Dr. Anil Diwan highlighted the company's nanoviricide platform and lead candidate NV-387, which has shown efficacy against multiple viruses and is preparing for Phase II trials targeting MPox with a potential market exceeding $17 billion by 2030.
Read full story

























